Compare Crispr Therapeutics AG (CRSP) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Emerson Electric Co. — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while Emerson Electric Co. trades at $162.23 (market cap $88.72B). The key difference: Emerson Electric Co. is far larger — about 18.2× Crispr Therapeutics AG's market cap, and Emerson Electric Co. pays a 1.4% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Emerson Electric Co. for 81 Days on average.
| CRSP | EMR | |
|---|---|---|
Market Cap | $4.88B | $88.72B |
Volume | 2,861,747 | 2,355,255 |
Sector | Health | Industrials |
52-Week High | $74.92 | $164.38 |
52-Week Low | $44.34 | $123.30 |
Typical Hold Time | 77 Days | 81 Days |
Enterprise Value | $3.30B | $99.80B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Emerson Electric (EMR) trades at $161.83, up 1.64% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 13.83% net income margin and a 12.81% ROE. Revenue is projected to grow to $18.6B in 2026, and the company maintains a solid balance sheet with $3.59B in cash. Analysts are largely positive, with a consensus price target of $165.90.
EMR presents a favorable outlook with upward earnings momentum and analyst support, though valuation multiples like a P/E of 34.81 suggest premium pricing. Risks include competitive pressures and macroeconomic volatility. The stock remains a candidate for growth-oriented investors seeking industrial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
